Immuneering Shares Rise After FDA Fast-Track Status for ...

Immuneering's stock rose 13% to $7.49 in premarket trading after receiving FDA fast-track designation for IMM-1-104, a treatment for pancreatic ductal adenocarcinoma, aimed at patients who have failed one line of treatment.